FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3045478434> ?p ?o ?g. }

• W3045478434 endingPage "164" @default.
• W3045478434 startingPage "157" @default.
• W3045478434 abstract "The fluoropyrimidine drug 5-Fluorouracil (5-FU) and the prodrug capecitabine have been extensively used for treatment of many types of cancer including colorectal, gastric, head and neck. Approximately, 10 to 25% of patients suffer from severe fluoropyrimidine-induced toxicity. This may lead to dose reduction and treatment discontinuation. Pharmacogenetics research could be useful for the identification of predictive markers in chemotherapy treatment. The aim of the study was to investigate the role of five genetic polymorphisms within two genes (DPYD, TYMS) in toxicity and efficacy of fluoropyrimidine-based chemotherapy.Total genomic DNA was extracted from 83 cancer patients treated with fluoropyrimidine-based chemotherapy. In this study, three polymorphisms were genotyped in dihydropyrimidine dehydrogenase gene c.1905+1 G>A (DPYD*2A; rs3918290), c.1679 T>G (I560S; DPYD*13; rs55886062), and c.2846A>T (D949V; rs67376798) and two polymorphisms, besides the Variable Number of Tandem Repeat (VNTR) polymorphism and 6-bp insertion/deletion polymorphism in thymidylate synthase gene. The analysis of polymorphisms for rs3918290, rs55886062, rs67376798 and 6-bp insertion/deletion in TYMS was done by Polymerase Chain Reaction-restriction Fragment Length Polymorphism (PCRRFLP) TYMS VNTR analysis. 5-FU-related toxicities such as anemia, febrile neutropenia, neurotoxicity, vomiting, nausea, and mucositis were evaluated according to NCI-CTC criteria version 4.0. T-test and chi-square were used and p-values less than 0.05 were considered statistically significant.DPYD gene polymorphisms were not observed in this study. The frequency of the TYMS +6 bp allele was 40.35% and the -6 bp allele was 59.65% in this study. The frequency of VNTR 2R allele was 48.75% and 3R allele was 51.15%. Toxicity grade II diarrhea, mucositis, nausea, vomiting, and neurotoxicity was 2.2, 24.1, 15.7, 6, and 51.8%, respectively. Thymidylate synthase ins/del polymorphisms were associated with increased grade III neurotoxicity (p=0.02). Furthermore, anemia grade III was significantly associated with 2R/2R genotype (0.009).Thymidylate synthase gene polymorphisms may play a key role in fluoropyrimidne -based chemotherapy. Although rare DPYD polymorphisms were not observed in our study, according to large population studies, DPYD gene polymorphisms could be used as a predictive biomarker for patient treatments." @default.
• W3045478434 created "2020-07-29" @default.
• W3045478434 creator A5028923299 @default.
• W3045478434 creator A5038967477 @default.
• W3045478434 creator A5046812782 @default.
• W3045478434 creator A5058994507 @default.
• W3045478434 creator A5063757795 @default.
• W3045478434 creator A5078196135 @default.
• W3045478434 creator A5079415493 @default.
• W3045478434 date "2020-07-23" @default.
• W3045478434 modified "2023-10-18" @default.
• W3045478434 title "The Role of Dihydropyrimidine Dehydrogenase and Thymidylate Synthase Polymorphisms in Fluoropyrimidine-Based Cancer Chemotherapy in an Iranian Population." @default.
• W3045478434 cites W1512974608 @default.
• W3045478434 cites W1789753761 @default.
• W3045478434 cites W1910446662 @default.
• W3045478434 cites W1965504402 @default.
• W3045478434 cites W1966968583 @default.
• W3045478434 cites W1976651872 @default.
• W3045478434 cites W1984328540 @default.
• W3045478434 cites W1990763949 @default.
• W3045478434 cites W1999974009 @default.
• W3045478434 cites W2001337137 @default.
• W3045478434 cites W2001603104 @default.
• W3045478434 cites W2010700304 @default.
• W3045478434 cites W2014636014 @default.
• W3045478434 cites W2031083378 @default.
• W3045478434 cites W2043315098 @default.
• W3045478434 cites W2047544514 @default.
• W3045478434 cites W2052593411 @default.
• W3045478434 cites W2060345683 @default.
• W3045478434 cites W2072657954 @default.
• W3045478434 cites W2088337613 @default.
• W3045478434 cites W2098584035 @default.
• W3045478434 cites W2105763971 @default.
• W3045478434 cites W2113414095 @default.
• W3045478434 cites W2121368761 @default.
• W3045478434 cites W2122747751 @default.
• W3045478434 cites W2125173168 @default.
• W3045478434 cites W2130146901 @default.
• W3045478434 cites W2134094359 @default.
• W3045478434 cites W2138849304 @default.
• W3045478434 cites W2139168548 @default.
• W3045478434 cites W2141923938 @default.
• W3045478434 cites W2147520342 @default.
• W3045478434 cites W2148894794 @default.
• W3045478434 cites W2154548748 @default.
• W3045478434 cites W2155535878 @default.
• W3045478434 cites W2158257131 @default.
• W3045478434 cites W2163478325 @default.
• W3045478434 cites W2168284699 @default.
• W3045478434 cites W2174633205 @default.
• W3045478434 cites W2180594955 @default.
• W3045478434 cites W2188907472 @default.
• W3045478434 cites W2284577602 @default.
• W3045478434 cites W2295950157 @default.
• W3045478434 cites W2316688895 @default.
• W3045478434 cites W2399203863 @default.
• W3045478434 cites W2566772267 @default.
• W3045478434 cites W2569370166 @default.
• W3045478434 cites W2777775302 @default.
• W3045478434 cites W2808401705 @default.
• W3045478434 cites W2912782925 @default.
• W3045478434 cites W2914199692 @default.
• W3045478434 cites W2917837889 @default.
• W3045478434 cites W2920902610 @default.
• W3045478434 cites W2922012035 @default.
• W3045478434 cites W4236891330 @default.
• W3045478434 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7368113" @default.
• W3045478434 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32695278" @default.
• W3045478434 hasPublicationYear "2020" @default.
• W3045478434 type Work @default.
• W3045478434 sameAs 3045478434 @default.
• W3045478434 citedByCount "4" @default.
• W3045478434 countsByYear W30454784342021 @default.
• W3045478434 countsByYear W30454784342022 @default.
• W3045478434 crossrefType "journal-article" @default.
• W3045478434 hasAuthorship W3045478434A5028923299 @default.
• W3045478434 hasAuthorship W3045478434A5038967477 @default.
• W3045478434 hasAuthorship W3045478434A5046812782 @default.
• W3045478434 hasAuthorship W3045478434A5058994507 @default.
• W3045478434 hasAuthorship W3045478434A5063757795 @default.
• W3045478434 hasAuthorship W3045478434A5078196135 @default.
• W3045478434 hasAuthorship W3045478434A5079415493 @default.
• W3045478434 hasConcept C104317684 @default.
• W3045478434 hasConcept C121608353 @default.
• W3045478434 hasConcept C123321153 @default.
• W3045478434 hasConcept C126322002 @default.
• W3045478434 hasConcept C135763542 @default.
• W3045478434 hasConcept C143998085 @default.
• W3045478434 hasConcept C2776694085 @default.
• W3045478434 hasConcept C2777909004 @default.
• W3045478434 hasConcept C2778050828 @default.
• W3045478434 hasConcept C2778496288 @default.
• W3045478434 hasConcept C2779655350 @default.
• W3045478434 hasConcept C2780456651 @default.
• W3045478434 hasConcept C526805850 @default.
• W3045478434 hasConcept C54355233 @default.
• W3045478434 hasConcept C55775858 @default.

• next